FrancophonIA/ELRC3.0 huggingface dataset:
English: The practice of coprophagy (consumption of faeces) that is part of rabbits behaviour/physiology may hypothetically have an impact on development of antimicrobial resistance.
Maltese: B'mod ipotetiku, il-prattika ta' koprofaġija (konsum ta' rawt) li huwa parti mill-imġiba/fiżjoloġija talfniek jista' jkollha impatt fuq l-iżvilupp ta' reżsitenza antimikrobjali.
English: The use of fluoroquinolones in rabbits may therefore have a higher risk on development of antimicrobial resistance, however this risk is theoretical.
Maltese: Għaldaqstant, l-użu ta' fluworokinoloni fil-fniek jista' jkollu riskju ogħla ta' żvilupp ta' reżistenza mikrobjali, madankollu dan irriskju huwa teoretiku.
English: Enrofloxacin 100 mg Oral solution Chickens (broilers),
Maltese: Enrofloxacin 100 mg Soluzzjoni orali
English: This observed decrease of susceptibility could either be explained by methodological factors, or it could reflect a true emergence of decreased susceptibility, that could be related to the use of enrofloxacin in rabbits or other animal species.
Maltese: Dan it-tnaqqis osservat ta' suxxettibilità jista' jiġi spjegat jew minn fatturi metodoloġiċi, jew jista' jirrifletti emerġenza reali ta' suxxettibilità mnaqqsa, relatata mal-użu ta' enrofloksaċina fi fniek jew speċi ta' annimali oħrajn.
English: Furthermore, as a consequence of restriction on availability, off-label use could be anticipated and this would compromise correct monitoring of use and reporting of adverse reactions.
Maltese: Barra minn hekk, minħabba r-restrizzjoni fuq id-disponibilità, jista' jkun mistenni l-użu mingħajr tikketta u dan ikun qed ixekkel il-monitoraġġ korrett tal-użu u r-rapportar tar-reazzjonijiet avversi.
English: In summary it may be concluded that today there is sufficient susceptibility to allow adequate treatment against the target animal pathogen Pasteurella.
Maltese: Fil-qosor, jista' jiġi konkluż li llum hemm biżżejjed suxxettibilità biex ikun jista' jsir trattament adegwat kontra l-patoġena tal-annimali fil-mira Pasteurella.
English: • the CVMP considered whether the benefit-risk ratio for HIPRALONA ENRO-S and its generics is positive when the products are administered to rabbits and whether the use of such highly critical antibiotics in a food producing species, used via oral route, is in line with the current recommendations to implement responsible use of antimicrobials.
Maltese: • is-CVMP ikkunsidra jekk il-proporzjon bejn il-benefiċċji u r-riskji għal HIPRALONA ENRO-S u l ġeneriċi tiegħu ikunx pożittiv meta l-prodotti jingħataw lill-fniek u jekk l-użu ta' antibijotiċi ferm kritiċi bħal dawn fi speċi li tipproduċi l-ikel, meħudin mill-ħalq, ikunx konformi marrakkomandazzjonijiet attwali dwar l-implimentazzjoni tal-użu responsabbli tal-antimikrobjali.
English: Furthermore, several studies were presented in order to address the susceptibility of different field strains of P. multocida to enrofloxacin.
Maltese: Barra dan, ġew ippreżentati diversi studji li jittrattaw is-suxxettibbiltà ta' razez varji ta' P. multocida għal enrofloksaċina.
English: Overall summary of the scientific evaluation of HIPRALONA ENRO-S and its generics intended for use in rabbits (see Annex I)
Maltese: Sommarju ġenerali tal-valutazzjoni xjentifika ta' HIPRALONA ENRO-S u l-ġeneriċi tiegħu maħsub għall-użu fil-fniek (ara lAnness I)
English: Lurrete.
Maltese: J.
English: The conclusion of this study was that the optimal dose for the treatment of respiratory infections caused by P. multocida in rabbits is 10 mg/kg bw for 5 consecutive days.
Maltese: Il-konklużjoni ta' dan l-istudju kienet li l-aħjar doża għall-kura ta' infezzjonijiet respiratorji kkawżati minn P. multocida fil-fniek hija 10 mg/kg bw għal ħamest ijiem konsekuttivi.
English: - The active substance is telmisartan.
Maltese: - Is-sustanza attiva hi telmisartan.
English: Possible side effects of telmisartan:
Maltese: Effetti sekondarji possibbli b'telmisartan:
English: Eastbourne, East Sussex, BN22 9AG United Kingdom
Maltese: Eastbourne, East Sussex, BN22 9AG Ir-Renju Unit
English: Date of first authorisation: 3 October 2011 Date of latest renewal: 9 June 2016
Maltese: Data tal-aħħar tiġdid: 9 ta' Ġunju 2016
English: Táncsics Mihály út 82 Hungary (Headquarters: 4042 Debrecen, Pallagi út 13)
Maltese: L-Ungerija (Kwartieri Ġenerali: 4042 Debrecen, Pallagi út 13)
English: The adjusted DBP changes from baseline were -8.4 (1.5) mm Hg, -4.5 (1.6) mm Hg and -3.5 (2.1) mm Hg respectively.
Maltese: Ilbidliet aġġustati tad-DBP mil-linja bażi kienu 8.4 (1.5) mm Hg, -4.5 (1.6) mm Hg u -3.5 (2.1) mm Hg, rispettivament.
English: A), poloxamers, meglumine, povidone (PVP K-30), sorbitol (E420), magnesium stearate
Maltese: Povidone (PVP K-30), sorbitol (E420), magnesium stearate
English: The other side of the tablet is debossed with the number "7459".
Maltese: Innaħa l-oħra tal-pillola mnaqqxa bin-numru "7459".
English: Telmisartan
Maltese: Telmisartan Teva
English: The other side of the tablet is debossed with the number "7460".
Maltese: Innaħa l-oħra tal-pillola mnaqqxa bin-numru "7460”.
English: • Amifostine (a protective medicine during radiotherapy for cancer treatment)
Maltese: • Amifostine(mediċina protettiva li tingħata waqt ir-radjuterapija għal pazjenti bil-kanċer) • Alkoħol
English: Cumulative urinary excretion is <1 % of dose.
Maltese: L-eliminazzjoni kumulattiva fl-awrina hi ta' < 1% taddoża.
English: Telmisartan Teva Pharma 20 mg tablets Telmisartan Teva Pharma 40 mg tablets Telmisartan Teva Pharma 80 mg tablets
Maltese: Telmisartan Teva Pharma 20 mg pilloli Telmisartan Teva Pharma 40 mg pilloli Telmisartan Teva Pharma 80 mg pilloli
English: Telmisartan was found to be similarly effective to ramipril in the pre-specified secondary endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.99 (97.5 % CI 0.90 - 1.08), p (non-inferiority) = 0.0004], the primary endpoint in the reference study HOPE (The Heart Outcomes Prevention Evaluation Study), which had investigated the effect of ramipril vs. placebo.
Maltese: Instab li telmisartan kien effettiv bl-istess mod bħal ramipril fir-riżultat aħħari sekondarju speċifikat minn qabel ta' mewt kardjovaskulari, infart mijokardijaku mhux fatali, u puplesija mhux fatali [0.99 (97.5% CI 0.90 - 1.08), p (non-inferjorità) = 0.0004], ir-riżultat aħħari primarju fl-istudju ta' referenza HOPE (The Heart Outcomes Prevention Evaluation Study), li kien investiga l-effett ta' ramipril vs.
English: Telmisartan Teva Pharma contains sodium
Maltese: Telmisartan Teva Pharma fih sodium
English: There was no evidence for benefit on cardiovascular mortality (hazard ratio 1.03, 95 % CI 0.85 - 1.24).
Maltese: (proporzjon ta' periklu ta' 1.03, 95% CI 0.85 - 1.24).
English: The Marketing Authorisation Holder is: Teva B.V.
Maltese: Id-Detentur tal-Awtorizzazzjoni għat-Tqegħid fis-Suq hu: Teva B.V.
English: Sími: +358 9 180 452 5900
Maltese: Ísland ratiopharm Oy Sími: +358 9 180 452 5900
English: Aluminium-Aluminium blisters : pack sizes of 28, 30 tablets
Maltese: Folji tal-aluminju-aluminju: daqsijiet tal-pakketti ta' 28, 30 pillola
English: The concomitant use of Telmisartan Teva Pharma with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Maltese: L-użu fl-istess ħin ta' Telmisartan Teva Pharma flimkien ma' prodotti li fihom aliskiren huwa kontraindikat f'pazjenti b'dijabete mellitus jew b'indeboliment tal-kliewi (GFR < 60 ml/min/1.73 m2) (ara sezzjonijiet 4.5 u 5.1).
English: Read the package leaflet for further information
Maltese: Kontenut tal-pakkett u informazzjoni oħra
English: Ísland ratiopharm Oy Finnland
Maltese: Suomi/Finland ratiopharm Oy Puh/Tel:
English: PC: SN: NN:
Maltese: (TPW) Tel.:
English: Aluminium-Aluminium blisters : pack sizes of 28 tablets
Maltese: Folji tal-aluminju-aluminju: daqsijiet tal-pakkett ta' 28 pillola
English: Currently available data are described in section 5.1 and 5.2 but no recommendation on a posology can be made.
Maltese: Attwalment id-dejta disponibbli hija deskritta fis-sezzjoni 5.1 u 5.2 iżda ma tista' ssir l-ebda rakkomandazzjoni dwar pożoloġija.
English: Pharmacokinetic objectives included the determination of the steady-state of telmisartan in children and adolescents, and investigation of age-related differences.
Maltese: L-għanijiet farmakokinetiċi inkludew id determinazzjoni tal-istadju fiss ta' telmisartan fit-tfal u l-adolexxenti, u investigazzjoni ta' differenzi relatati mal-età.
English: As with other medicinal products acting on the renin-angiotensin-aldosterone system, telmisartan may provoke hyperkalaemia (see section 4.4).
Maltese: telmisartan jista' jipprovoka iperkalemija (ara sezzjoni 4.4).
English: Renal impairment including acute renal failure
Maltese: Indeboliment renali u trapjant renali
English: Telmisartan Teva Pharma contains sorbitol.
Maltese: Telmisartan Teva Pharma fih is-sorbitol
English: Telmisartan Teva Pharma is contraindicated in patients with severe hepatic impairment (see section 4.3).
Maltese: Indeboliment epatiku Telmisartan Teva Pharma hu kontraindikat f'pazjenti b'indeboliment serju tal-fwied (ara sezzjoni 4.3).
English: By inclusion the presence of secondary hypertension was not investigated.
Maltese: Permezz tal-inklużjoni, il-preżenza ta' pressjoni għolja sekondarja ma ġietx investigata.
English: Alternatively, Telmisartan Teva Pharma may be used in combination with diuretics (“water” tablets) such as hydrochlorothiazide which have been shown to have an additive blood pressure lowering effect with Telmisartan Teva Pharma.
Maltese: Inkella, Telmisartan Teva Pharma jista' jintuża flimkien ma' dijuretiċi (“pilloli tal ilma”), bħal hydrochlorothiazide li ntwera li għandhom effett addizzjonali li jnaqqsu l-pressjoni taddemm b'Telmisartan Teva Pharma.
English: Telmisartan Teva Pharma 20 mg tablets This medicine contains 21.4 mg sorbitol in each tablet.
Maltese: Telmisartan Teva Pharma 20 mg pilloli Din il-mediċina fiha 21.4 mg sorbitol f'kull pillola.
English: • Medicines that may increase blood potassium levels such as salt substitutes containing potassium, potassium-sparing diuretics (certain ‘water tablets'), ACE inhibitors, angiotensin II receptor antagonists, NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen), heparin, immunosuppressives (e.g. cyclosporin or tacrolimus), and the antibiotic trimethoprim.
Maltese: • Mediċini li jistgħu jżidu l-livelli ta' potassju fid-demm bħal sostituti għall-melħ li fihom il-potassju, dijuretiċi li jirristrinġu t-tnixxija ta' potassju (ċertu ‘pilloli tal-ilma'), impedituri ta' ACE, antagonisti riċettaturi ta' aniotensin II, NSAIDS (mediċini ta' kontra l-infjammazzjoni mhux sterojdi eż. aspirina jew ibuprofen), eparina, immunosoppressivi (eż. cyclosporin jew tacrolimus) u l-antibijotiku trimethoprim.
English: After adjustment for age group effects mean SBP changes from baseline (primary objective) were -14.5 (1.7) mm Hg in the telmisartan 2 mg/kg group, -9.7 (1.7) mm Hg in the telmisartan 1 mg/kg group, and -6.0 (2.4) in the placebo group.
Maltese: Wara l-aġġustament għall-effetti tal-grupp tal-età il-bidliet medji tal-SBP mil-linja bażi (għan ewlieni) kienu -14.5 (1.7) mm Hg fil-grupp ta' telmisartan 2 mg/kg, -9.7 (1.7) mm
English: In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function), the co-administration of angiotensin II receptor antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible.
Maltese: F'xi pazjenti li għandhom il-funzjoni renali kompromessa (eż. pazjenti deidratati jew pazjenti anzjani b'funzjoni renali kompromessa), l-għoti flimkien ta' antagonisti ta' angiotensin II u mediċini li jinibixxu cyclo-oxygenase, jista' jirriżulta f'deterjorament addizzjonali tal-funzjoni renali, li jinkludi lpossibbiltà ta' insuffiċjenza akuta renali, li normalment tkun riversibbli.
English: The overall incidence of adverse reactions reported with telmisartan was usually comparable to placebo (41.4% vs 43.9 %) in controlled trials in patients treated for hypertension.
Maltese: L-inċidenza ta' reazzjonijiet avversi rrappurtati b'telmisartan kienet ġeneralment komparabbli mal plaċebo (41.4% vs 43.9%) fil-provi kkontrollati f'pazjenti kkurati għal pressjoni għolja.
English: **Cases of progressive scarring of lung tissue have been reported during intake of telmisartan.
Maltese: **Każijiet ta' ċikatriċi progressivi tat-tessut tal-pulmun ġew irrappurtati waqt it-teħid ta' telmisartan.
English: Other medicines and Telmisartan Teva Pharma
Maltese: Mediċini oħra u Telmisartan Teva Pharma
English: The safety data from this study in patients aged 6 to < 18 years appeared generally similar to that observed in adults.
Maltese: Id-dejta tas-sigurtà minn dan l-istudju f'pazjenti li għandhom 6 sa < 18-il sena ġeneralment dehret simili għal dik osservata fl-adulti.
English: Magnesium stearate
Maltese: mg kuljum.
English: • Lithium containing medicines to treat some types of depression.
Maltese: • Mediċini li fihom il-litju sabiex jittrattaw xi tipi ta' dipressjoni.
English: Telmisartan Teva Pharma 80 mg tablets This medicine contains 85.6 mg sorbitol in each tablet.
Maltese: Telmisartan Teva Pharma 80 mg pilloli Din il-mediċina fiha 85.6 mg sorbitol f'kull pillola.
English: See also information under the heading “Do not take Telmisartan Teva Pharma”.
Maltese: Ara wkoll l-informazzjoni taħt l-intestatura “Tiħux Temlisartan Teva Pharma”.
English: Potassium sparing diuretics e.g. spironolactone, eplerenone, triamterene, or amiloride, potassium supplements, or potassium-containing salt substitutes may lead to a significant increase in serum potassium.
Maltese: II. Dijuretiċi li jirristringu t-tnixxija ta' potassju, eż. spironolactone, eplerenone, triamterene, jew amiloride, supplimenti tal-potassju, jew sostituti tal-melħ li fihom il-potassju jistgħu jwasslu għal żieda sinifikanti fil-potassju fis-serum.
English: The blood pressure lowering effects of two doses of telmisartan were assessed in 76 hypertensive, largely overweight patients aged 6 to < 18 years (body weight ≥ 20 kg and ≤ 120 kg, mean 74.6 kg), after taking telmisartan 1 mg/kg (n = 29 treated) or 2 mg/kg (n = 31 treated) over a four-week treatment period.
Maltese: ≤ 120 kg, medja ta' 74.6 kg), wara li ħadu telmisartan 1 mg/kg (n = 29 kkurati) jew 2 mg/kg (n = 31
English: How to store Telmisartan Teva Pharma
Maltese: Tiħux Telmisartan Teva Pharma
English: Telmisartan Teva Pharma 40 mg tablets
Maltese: Telmisartan Teva Pharma 40 mg pilloli
English: This medicine contains 85.6 mg sorbitol in each tablet.
Maltese: Din il-mediċina fiha 85.6 mg sorbitol f'kull pillola.
English: When Telmisartan Teva Pharma is used in patients with impaired renal function, periodic monitoring of potassium and creatinine serum levels is recommended.
Maltese: Meta Telmisartan Teva Pharma jintuża f'pazjenti li għandhom indeboliment fil-funzjoni renali, monitoraġġ perjodiku tal-livelli tal-potassju u tal-kreatinina tas-serum hu rakkomandat.
English: Telmisartan Teva Pharma is also provided in aluminium-aluminium blister packs of 28 and 30 tablets.
Maltese: Telmisartan Teva Pharma jiġi wkoll f'pakketti b'folji tal-aluminju-aluminju bi 28 u 30 pillola.
English: Telmisartan Teva Pharma 40 mg tablets This medicine contains 42.8 mg sorbitol in each tablet.
Maltese: Telmisartan Teva Pharma 40 mg pilloli Din il-mediċina fiha 42.8 mg sorbitol f'kull pillola.
English: Pack sizes of 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tablets for perforated blisters.
Maltese: Daqsijiet tal-pakketti ta' 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 pillola għallfolji perforati li jistgħu jitqaxxru.
English: 14x1 tablets 28x1 tablets 30x1 tablets 40x1 tablets 56x1 tablets 60x1 tablets 84x1 tablets 90x1 tablets 98x1 tablets 100x1 tablets 30 tablets 28 tablets
Maltese: 14x1 pilloli 28x1 pilloli 30x1 pilloli 40x1 pilloli 56x1 pilloli 60x1 pilloli 84x1 pilloli 90x1 pilloli 98x1 pilloli 100x1 pilloli 30 pillola 28 pillola
English: This medicine contains 21.4 mg sorbitol in each tablet.
Maltese: Din il-mediċina fiha 21.4 mg sorbitol f'kull pillola.
English: Each Telmisartan Teva Pharma tablet contains 40 mg telmisartan.
Maltese: Kull pillola ta' Telmisartan Teva Pharma fiha, 40 mg telmisartan.
English: Telmisartan Teva Pharma 40 mg tablets telmisartan
Maltese: Telmisartan Teva Pharma 40 mg pilloli telmisartan
English: Medicinal products or therapeutic classes of medicinal products that may provoke hyperkalaemia are salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti-inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim.
Maltese: antagonisti tar-riċetturi ta' angiotensin II, mediċini mhux sterojdi kontra l-infjammazzjoni (NSAIDs li jinkludu inibituri COX-2 selettivi), eparina, immunosoppressuri (cyclosporin jew tacrolimus), u trimethoprim).
English: In the “Prevention Regimen For Effectively avoiding Second Strokes” (PRoFESS) trial in patients 50 years and older, who recently experienced stroke, an increased incidence of sepsis was noted for telmisartan compared with placebo, 0.70 % vs. 0.49 % [RR 1.43 (95 % confidence interval 1.00 - 2.06)]; the incidence of fatal sepsis cases was increased for patients taking telmisartan (0.33 %) vs. patients taking placebo (0.16 %) [RR 2.07 (95 % confidence interval 1.14 - 3.76)].
Maltese: Fil-prova PRoFESS, “Programm ta' kura preventiva sabiex jiġu evitati b'mod effettiv attakki sekondarji”, li saret fuq pazjenti li għandhom 50 sena jew aktar, li riċentement kellhom attakk pupletiku, ġie nnotat li kien hemm inċidenza ogħla ta' sepsis għal telmisartan meta mqabbel mal plaċebo, 0.70 % kontra 0.49 % [RR 1.43 (95 % interval ta' kunfidenza 1.00 - 2.06)]: l-inċidenza ta'
English: Telmisartan Teva Pharma 20 mg tablets
Maltese: Telmisartan Teva Pharma 20 mg pilloli
English: Hypotension2, orthostatic hypotension
Maltese: Stenosi tal-valv mitrali u aortiku, kardjomijopatija ipertropika ostruttiva
English: Telmisartan Teva Pharma 80 mg tablets
Maltese: Telmisartan Teva Pharma 80 mg pilloli
English: 14x1 tablets 28x1 tablets 30x1 tablets 40x1 tablets 56x1 tablets 60x1 tablets 84x1 tablets 90x1 tablets 98x1 tablets 100x1 tablets 28 tablets
Maltese: 14x1 pilloli 28x1 pilloli 30x1 pilloli 40x1 pilloli 56x1 pilloli 60x1 pilloli 84x1 pilloli 90x1 pilloli 98x1 pilloli 100x1 pilloli 28 pillola
English: - Keep this leaflet.
Maltese: periklu ta' 0.
English: Telmisartan Teva Pharma 20 mg tablets telmisartan
Maltese: Telmisartan Teva Pharma 20 mg pilloli telmisartan
English: Telmisartan Teva Pharma 80 mg tablets telmisartan
Maltese: Telmisartan Teva Pharma 80 mg pilloli telmisartan
English: When telmisartan is taken with food, the reduction in the area under the plasma concentration-time curve (AUC0-∞) of telmisartan varies from approximately 6 % (40 mg dose) to approximately 19 % (160 mg dose).
Maltese: Meta telmisartan jittieħed mal-ikel, it-tnaqqis taż-żona taħt il-kurva tal-konċentrazzjoni tal-plażma-żmien (AUC0-∞) ta' telmisartan tvarja minn madwar 6% (doża ta' 40mg) sa madwar 19% (doża ta' 160mg).
English: EU/1/11/719/011 14x1 tablets EU/1/11/719/012 28x1 tablets EU/1/11/719/013 30x1 tablets EU/1/11/719/014 40x1 tablets EU/1/11/719/015 56x1 tablets EU/1/11/719/016 60x1 tablets EU/1/11/719/017 84x1 tablets EU/1/11/719/018 90x1 tablets EU/1/11/719/019 98x1 tablets EU/1/11/719/020 100x1 tablets EU/1/11/719/063 28 tablets
Maltese: EU/1/11/719/011 14x1 pilloli EU/1/11/719/012 28x1 pilloli EU/1/11/719/013 30x1 pilloli EU/1/11/719/014 40x1 pilloli EU/1/11/719/015 56x1 pilloli EU/1/11/719/016 60x1 pilloli EU/1/11/719/017 84x1 pilloli EU/1/11/719/018 90x1 pilloli EU/1/11/719/019 98x1 pilloli EU/1/11/719/020 100x1 pilloli EU/1/11/719/063 28 pillola
English: EU/1/11/719/031 14x1 tablets EU/1/11/719/032 28x1 tablets EU/1/11/719/033 30x1 tablets EU/1/11/719/034 40x1 tablets EU/1/11/719/035 56x1 tablets EU/1/11/719/036 60x1 tablets EU/1/11/719/037 84x1 tablets EU/1/11/719/038 90x1 tablets EU/1/11/719/039 98x1 tablets EU/1/11/719/040 100x1 tablets EU/1/11/719/061 30 tablets EU/1/11/719/064 28 tablets
Maltese: EU/1/11/719/031 14 x 1 pilloli EU/1/11/719/032 28 x 1 pilloli EU/1/11/719/033 30 x 1 pilloli EU/1/11/719/034 40 x 1 pilloli EU/1/11/719/035 56 x 1 pilloli EU/1/11/719/036 60 x 1 pilloli EU/1/11/719/037 84 x 1 pilloli EU/1/11/719/038 90 x 1 pilloli EU/1/11/719/039 98 x 1 pilloli EU/1/11/719/040 100 x 1 pilloli EU/1/11/719/061 30 pillola EU/1/11/719/064 28 pillola
English: Telmisartan Teva Pharma 40 mg tablets EU/1/11/719/021 Cartons of 14x1 tablets in peelable perforated unit-dose aluminiumaluminium blisters EU/1/11/719/022 Cartons of 28x1 tablets in peelable perforated unit-dose aluminiumaluminium blisters EU/1/11/719/023 Cartons of 30x1 tablets in peelable perforated unit-dose aluminiumaluminium blisters EU/1/11/719/024 Cartons of 40x1 tablets in peelable perforated unit-dose aluminiumaluminium blisters EU/1/11/719/025 Cartons of 56x1 tablets in peelable perforated unit-dose aluminiumaluminium blisters EU/1/11/719/026 Cartons of 60x1 tablets in peelable perforated unit-dose aluminiumaluminium blisters EU/1/11/719/027 Cartons of 84x1 tablets in peelable perforated unit-dose aluminiumaluminium blisters EU/1/11/719/028 Cartons of 90x1 tablets in peelable perforated unit-dose aluminiumaluminium blisters EU/1/11/719/029 Cartons of 98x1 tablets in peelable perforated unit-dose aluminiumaluminium blisters EU/1/11/719/030 Cartons of 100x1 tablets in peelable perforated unit-dose aluminiumaluminium blisters EU/1/11/719/031 Cartons of 14x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/11/719/032 Cartons of 28x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/11/719/033 Cartons of 30x1 tablets in perforated unit-dose aluminium-aluminium blisters EU/1/11/719/034 Cartons of 40x1 tablets in perforated unit-dose aluminium-aluminium blisters
Maltese: Kaxxi tal-kartun ta' 56x1 pillola f'folji perforati ta' doża waħda li jistgħu jitqaxxru magħmulin minn aluminju-aluminju EU/1/11/719/026 Kaxxi tal-kartun ta' 60x1 pillola f'folji perforati ta' doża waħda li jistgħu jitqaxxru magħmulin minn aluminju-aluminju EU/1/11/719/027 Kaxxi tal-kartun ta' 84x1 pillola f'folji perforati ta' doża waħda li jistgħu jitqaxxru magħmulin minn aluminju-aluminju EU/1/11/719/028 Kaxxi tal-kartun ta' 90x1 pillola f'folji perforati ta' doża waħda li jistgħu jitqaxxru magħmulin minn aluminju-aluminju EU/1/11/719/029 Kaxxi tal-kartun ta' 98x1 pillola f'folji perforati ta' doża waħda li jistgħu jitqaxxru magħmulin minn aluminju-aluminju EU/1/11/719/030 Kaxxi tal-kartun ta' 100x1 pillola f'folji perforati ta' doża waħda li jistgħu jitqaxxru magħmulin minn aluminju-aluminju
English: Contents of the pack and other information What Telmisartan Teva Pharma contains
Maltese: Kontenut tal-pakkett u informazzjoni oħra X'fih Telmisartan Teva Pharma
English: This medicine contains 42.8 mg sorbitol in each tablet.
Maltese: Din il-mediċina fiha 42.8 mg sorbitol f'kull pillola.
English: Each Telmisartan Teva Pharma tablet contains 20 mg telmisartan.
Maltese: Kull pillola ta' Telmisartan Teva Pharma fiha 20 mg telmisartan.
English: The safety and efficacy of Telmisartan Teva Pharma in children and adolescents aged below 18 years have not been established.
Maltese: Is-sigurtà u l-effikaċja ta' Telmisartan Teva Pharma fit-tfal u l-adolexxenti li għandhom anqas minn 18-il sena ma ġewx determinati s'issa.